Table 2.
Parameter | Criterion Standard (CS) | BIOMECA Test | Center | Positive CS and BIOMECA test (N) | Positive CS/ Negative BIOMECA test (N) | Sensitivity (95% CI) | Negative CS and BIOMECA test (N) | Negative CS and Positive BIOMECA test (N) | Specificity (95% CI) | No result (BIOMECA test) (N) | BIOMECA Accuracy (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
PFA Diagnosis in confirmed PF ependymoma | MA | H3K27me3 IHC | Austria | 94 | 1 | 99.0 (94.3–100) | 10 | 0 | 100 (69.2–100) |
1 | 99.1 |
Germany | 94 | 0 | 100 (96.2–100) | 8 | 0 | 100 (63.2–100) |
4 | 100 | |||
UK | 94 | 1 | 99.0 (94.3–100) | 9 | 1 | 90.0 (55.5–99.8) | 1 | 98.1 | |||
TNC IHC | Austria | 94 | 2 | 97.9 (92.7–99.8) | 6 | 4 | 60 (26.2–87.9) | 0 | 94.3 | ||
France | 88 | 8 | 91.7 (84.2–96.3) | 7 | 3 | 70 (34.8–93.3) | 0 | 89.6 | |||
Chromosome 1q Gain across all molecular diagnoses | MA | 1q FISH | UK | 9 | 6 | 60.0 (32.3–83.7 | 93 | 4 | 95.9 (89.8–98.9) | 17 | 91.1 |
France | 15 | 3 | 83.3 (58.6–96.4) | 67 | 12 | 84.8 (75.0–91.9) | 32 | 84.5 | |||
MLPA | UK | 18 | 1 | 94.7 (74–99.9) | 109 | 0 | 100 (96.7–100) | 1 | 99.2 | ||
MIP | Germany | 18 | 1 | 94.7 (74–99.9) |
110 | 0 | 100 (96.7–100) | 0 | 99.2 | ||
Diagnosis of ST EPN with gene fusions with RELA | MA plus targeted profiling for RELA | p65 IHC | Germany | 18 | 0 | 100 (81.5–100) | 6 | 0 | 100 (54.1–100) | 1 | 100 |
France | 16 | 2 | 88.9 (65.6–98.6) | 6 | 1 | 85.7 (42.1–99.6) | 0 | 88 |
CS, Criterion Standard; MA, DNA Methylation Array; PF, Posterior Fossa; ST, Supratentorial; IHC, Immunohistochemistry; FISH, Fluorescent In Situ Hybridization; CI, Confidence Interval.